Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.
Doxorubucin is an effective therapeutic in cancer treatment, but it can cause cardiotoxicity and damage the mitochondrial machinery. A new patient-derived and mitochondria-rich human induced pluripotent stem cell derived-cardiomyocyte (hiPSC-CM) model protected by dexrazoxane was developed.
Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth. Several VEGFR-2 inhibitors have already been licensed for the clinic.
In gout, excessive levels of uric acid in the blood lead to deposition of urate crystals in joints, which can cause strong inflammatory pain. Effectively treating gout involves mitigating not only the pain due to inflammatory responses, but also reducing uric acid levels in the blood, such as by inhibiting the uric acid transporter URAT1.
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and co-inhibitory pathways to enhance antitumor responses.
At the ongoing International Society for Stem Cell Research meeting, Chinese researchers reported they demonstrated that SPT6 homolog, histone chaperone and transcription elongation factor (SPT6) promotes epidermal stem/progenitor cells differentiation by facilitating transcriptional elongation, but its role in vivo in skin homeostasis is not well defined.
IgA nephropathy is a progressive kidney disease characterized by the deposition of immune complexes containing IgA, where a proliferation-inducing ligand (APRIL) drives the production of pathogenic IgA. Jade Biosciences Inc. has developed a novel APRIL-binding therapeutic, JADE-101, for the treatment of IgA nephropathy.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the need for innovative therapeutic approaches. CD97 is a cell surface protein with broad, increased expression on AML cells compared to normal blood stem and progenitor cells. Moreover, CD97 overexpression in AML patients has been associated with poor survival, thus emerging as a potential therapeutic target.
Researchers at Korea Research Institute of Chemical Technology and University of Ulsan have described UBA6-specific E2 conjugating enzyme 1 (USE1) inhibitors reported to be useful for the treatment of cancer.
RSS
